Page last updated: 2024-11-03

protoporphyrin ix and Erythema

protoporphyrin ix has been researched along with Erythema in 16 studies

protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.

Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.

Research Excerpts

ExcerptRelevanceReference
"Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment."9.20Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015)
"To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT."9.14Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010)
" Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin."7.80Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014)
"Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment."5.20Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015)
" Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated."5.19Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014)
"To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT."5.14Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010)
"To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris."5.13Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial. ( Haedersdal, M; Togsverd-Bo, K; Wiegell, SR; Wulf, HC, 2008)
" Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin."3.80Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014)
"Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for skin cancer, yet ALA dosing is crude."1.30Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. ( Anderson, RR; Kollias, N; Rhodes, LE; Tsoukas, MM, 1997)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's5 (31.25)29.6817
2010's10 (62.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mallidi, S1
Anbil, S1
Lee, S1
Manstein, D1
Elrington, S1
Kositratna, G1
Schoenfeld, D1
Pogue, B1
Davis, SJ1
Hasan, T2
Petersen, B3
Wiegell, SR5
Wulf, HC7
Lerche, CM1
Fabricius, S1
Philipsen, PA1
Woods, JA1
Ferguson, JS1
Kalra, S1
Degabriele, A1
Gardner, J1
Logan, P1
Ferguson, J1
Kanick, SC1
Davis, SC1
Zhao, Y1
Sheehan, KL1
Maytin, EV1
Pogue, BW1
Chapman, MS1
Heerfordt, IM2
Nissen, CV1
Mikkelsen, CS1
Mikolajewska, P2
Iani, V2
Juzeniene, A2
Moan, J2
Donnelly, RF1
Garland, MJ1
Morrow, DI1
Singh, TR1
Bissonnette, R1
Tremblay, JF1
Juzenas, P1
Boushira, M1
Lui, H1
Choudry, K1
Brooke, RC1
Farrar, W1
Rhodes, LE3
Haedersdal, M1
Togsverd-Bo, K1
Tsoukas, MM1
Anderson, RR1
Kollias, N1
Gerscher, S1
Connelly, JP1
Beijersbergen Van Henegouwen, GM1
MacRobert, AJ1
Watt, P1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737]43 participants (Actual)Interventional2019-11-01Completed
Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570]218 participants (Anticipated)Observational2022-12-01Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

9 trials available for protoporphyrin ix and Erythema

ArticleYear
Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
    The British journal of dermatology, 2014, Volume: 171, Issue:1

    Topics: Aminolevulinic Acid; Drug Eruptions; Erythema; Female; Fluorescence; Humans; Keratosis, Actinic; Mal

2014
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
    The British journal of dermatology, 2014, Volume: 171, Issue:6

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C

2014
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4

    Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos

2015
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4

    Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos

2015
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4

    Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos

2015
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4

    Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos

2015
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
    The British journal of dermatology, 2016, Volume: 174, Issue:5

    Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum

2016
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
    The British journal of dermatology, 2017, Volume: 176, Issue:5

    Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce

2017
Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.
    Pharmaceutical research, 2010, Volume: 27, Issue:10

    Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Erythema; Female; Humans; Light; Male; Needle

2010
Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.
    The Journal of investigative dermatology, 2002, Volume: 119, Issue:1

    Topics: Administration, Oral; Aminolevulinic Acid; Apoptosis; CD3 Complex; Epidermis; Erythema; Humans; Phot

2002
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
    The British journal of dermatology, 2003, Volume: 149, Issue:1

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car

2003
Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
    Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:3

    Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Edema; Erythema; Female; Fluorescence; Humans; Laser Ther

2008

Other Studies

7 other studies available for protoporphyrin ix and Erythema

ArticleYear
Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.
    Journal of biomedical optics, 2014, Volume: 19, Issue:2

    Topics: Adult; Aminolevulinic Acid; Erythema; Female; Humans; Male; Photochemotherapy; Photosensitizing Agen

2014
Correlation between treatment time, photobleaching, inflammation and pain after photodynamic therapy with methyl aminolevulinate on tape-stripped skin in healthy volunteers.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2015, Volume: 14, Issue:5

    Topics: Adult; Aminolevulinic Acid; Erythema; Fluorescence; Forearm; Humans; Inflammation; Male; Middle Aged

2015
The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
    Journal of photochemistry and photobiology. B, Biology, 2015, Volume: 151

    Topics: Cell Line; Chlorpromazine; Chromatography, High Pressure Liquid; Dermatitis, Phototoxic; Dexamethaso

2015
Protoporphyrin IX in the skin measured noninvasively predicts photosensitivity in patients with erythropoietic protoporphyria.
    The British journal of dermatology, 2016, Volume: 175, Issue:6

    Topics: Case-Control Studies; Erythema; Female; Fluorescence; Humans; Male; Photobleaching; Protoporphyria,

2016
Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
    The British journal of dermatology, 2009, Volume: 161, Issue:5

    Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Erythema; Humans; Lasers; Mice; Mice,

2009
Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin.
    The Journal of investigative dermatology, 1997, Volume: 108, Issue:1

    Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Erythema; Female; Fluorescent Dye

1997
A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylester.
    The British journal of dermatology, 2001, Volume: 144, Issue:5

    Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; Erythema; Female; Humans; Iontophoresi

2001